Table 3.

Biophysical properties of bococizumab VH CDR2 variant antibodies. The top 12 enriched bococizumab VH CDR2 variant antibodies were expressed and purified and tested in an AC-SINS assay, HPLC-SEC and a specificity ELISA. Antibody variants are named according to the amino acid identity at positions 52, 54 and 57. Values shown are relative enrichment of clones in high mammalian display population, the AC-SINS wavelength shift (nm), the HPLC-SEC column retention volume (Vr (ml) in 2xPBS and an ELISA signal for binding to bovine serum albumin-blocked polystyrene microtiter plate wells

CDR2 sequence	Clone name	Relative enrichment	AC-SINS (nm)	Vr (ml)	Specificity ELISA signal (RFU)
INPEGGIT	NEI	69	5	1.49	30
IEPEGGHT	EEH	65	4	1.49	190
INPEGGET	NEE	32	4	1.48	320
IEPAGGET	EAE	20	4	1.51	570
INPFGGGT	NFG	17	18	1.53	1700
IMPVGGET	MVE	16	4	1.50	30
IQPLGGDT	QLD	15	5	1.50	580
IIPDGGQT	IDQ	14	4	1.49	100
IAPEGGIT	AEI	13	5	1.49	400
IIPDGGPT	IDP	12	4	1.49	1900
IKPDGGST	KDS	12	5	1.50	480
IEPTGGVT	ETV	12	5	1.50	390
ISPFGGRT	Bococizumab (SFR)	-	31	1.61	215,000
INPSGGRT	5A10i (NSR)	-	5	1.49	140
N/A	Alirocumab	-	4	1.50	410